What is the evidence for using hemostatic agents in surgery?
The pharmacological methods used to achieve systemic hemostasis have generated much discussion due to concerns of serious adverse effects (e.g., thromboembolic complications) and costs of therapy in addition to efficacy considerations. There are a limited number of well-controlled trials involving pharmacological hemostasis for spine surgery. In the largest double-blinded randomized controlled trial to date involving spine surgery, there was a trend toward reduced homologous transfusion in patients receiving aprotinin, but the only statistically significant result ( p<0.001) was a reduction in autologous red cell donations. The findings of this trial are important, since the investigators used a number of restrictive transfusion strategies (e.g., autologous donation, low hematocrit trigger for transfusion, blood-salvaging procedures with the exception of no cell saver) that were not always employed in earlier trials involving hemostatic agents. Smaller studies involving antifibrinolytic agents other than aprotinin have demonstrated reductions in blood loss and transfusion requirements in patients undergoing spine surgery, although the results were not always statistically significant. A very large randomized trial would be required to address comparative medication- and transfusion-related adverse events; such a trial involving patients undergoing cardiac surgery is currently being performed. Additionally, cost-effectiveness analyses are needed to help define the role of these agents based on the data that is available.
Erstad
Brian L
BL
Department of Pharmacy Practice and Science, College of Pharmacy, Tucson, Arizona 85721-0207, USA. erstad@pharmacy.arizona.edu.
D007611:Aprotinin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004311:Double-Blind Method; D006488:Hemostasis, Surgical / Q000191:economics / Q000379:methods; D006490:Hemostatics / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013131:Spine / Q000601:surgery*; D016896:Treatment Outcome
D006490:Hemostatics; D007611:Aprotinin